$5.43
+0.65
(+13.6%)▲
13.44%
Downside
Day's Volatility :15.77%
Upside
2.69%
27.81%
Downside
52 Weeks Volatility :75.47%
Upside
66.02%
Period | Treace Medical Concepts Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -24.49% | -2.1% | 0.0% |
6 Months | -57.36% | 4.9% | 0.0% |
1 Year | -55.9% | 16.0% | 0.0% |
3 Years | -80.27% | 10.0% | -26.4% |
Market Capitalization | 297.9M |
Book Value | $1.80 |
Earnings Per Share (EPS) | -1.02 |
Wall Street Target Price | 6.88 |
Profit Margin | -32.08% |
Operating Margin TTM | -48.1% |
Return On Assets TTM | -17.02% |
Return On Equity TTM | -48.6% |
Revenue TTM | 198.5M |
Revenue Per Share TTM | 3.21 |
Quarterly Revenue Growth YOY | 6.0% |
Gross Profit TTM | 114.3M |
EBITDA | -57.9M |
Diluted Eps TTM | -1.02 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.94 |
EPS Estimate Next Year | -0.77 |
EPS Estimate Current Quarter | -0.29 |
EPS Estimate Next Quarter | -0.26 |
What analysts predicted
Upside of 26.7%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 39.4M | - |
Net Income | -5.1M | - |
Net Profit Margin | -12.95% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 57.4M | ↑ 45.54% |
Net Income | -6.4M | ↑ 26.22% |
Net Profit Margin | -11.24% | ↑ 1.71% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 94.4M | ↑ 64.59% |
Net Income | -24.6M | ↑ 281.88% |
Net Profit Margin | -26.07% | ↓ 14.83% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 141.8M | ↑ 50.22% |
Net Income | -47.3M | ↑ 92.17% |
Net Profit Margin | -33.35% | ↓ 7.28% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 187.1M | ↑ 31.92% |
Net Income | -49.5M | ↑ 4.71% |
Net Profit Margin | -26.47% | ↑ 6.88% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 42.2M | ↓ 15.22% |
Net Income | -13.1M | ↑ 275.74% |
Net Profit Margin | -31.12% | ↓ 24.1% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 42.0M | ↓ 0.57% |
Net Income | -12.3M | ↓ 6.56% |
Net Profit Margin | -29.25% | ↑ 1.87% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 40.8M | ↓ 2.85% |
Net Income | -17.5M | ↑ 42.78% |
Net Profit Margin | -42.99% | ↓ 13.74% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 62.2M | ↑ 52.64% |
Net Income | -6.3M | ↓ 64.15% |
Net Profit Margin | -10.1% | ↑ 32.89% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 51.1M | ↓ 17.85% |
Net Income | -18.7M | ↑ 197.34% |
Net Profit Margin | -36.54% | ↓ 26.44% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 44.5M | ↓ 13.02% |
Net Income | -21.2M | ↑ 13.55% |
Net Profit Margin | -47.7% | ↓ 11.16% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 29.7M | - |
Total Liabilities | 26.6M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 41.8M | ↑ 40.69% |
Total Liabilities | 41.0M | ↑ 54.51% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 140.8M | ↑ 236.84% |
Total Liabilities | 47.7M | ↑ 16.37% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 159.0M | ↑ 12.93% |
Total Liabilities | 98.5M | ↑ 106.28% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 251.9M | ↑ 58.41% |
Total Liabilities | 114.0M | ↑ 15.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 249.2M | ↑ 56.69% |
Total Liabilities | 91.6M | ↓ 7.05% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 249.6M | ↑ 0.19% |
Total Liabilities | 99.7M | ↑ 8.88% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 240.4M | ↓ 3.72% |
Total Liabilities | 102.5M | ↑ 2.82% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 251.9M | ↑ 4.8% |
Total Liabilities | 114.0M | ↑ 11.19% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 242.7M | ↓ 3.64% |
Total Liabilities | 116.3M | ↑ 2.08% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 226.1M | ↓ 6.86% |
Total Liabilities | 113.9M | ↓ 2.06% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.7M | - |
Investing Cash Flow | -1.2M | - |
Financing Cash Flow | 19.7M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.5M | ↓ 41.43% |
Investing Cash Flow | -1.1M | ↓ 11.73% |
Financing Cash Flow | 11.5M | ↓ 41.72% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.2M | ↑ 282.58% |
Investing Cash Flow | -2.7M | ↑ 153.04% |
Financing Cash Flow | 107.7M | ↑ 835.86% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -30.6M | ↑ 78.26% |
Investing Cash Flow | -76.5M | ↑ 2728.76% |
Financing Cash Flow | 20.8M | ↓ 80.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.3M | ↑ 222.12% |
Investing Cash Flow | -80.5M | ↑ 25.73% |
Financing Cash Flow | 107.9M | ↑ 36222.9% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.3M | ↓ 51.71% |
Investing Cash Flow | -10.4M | ↓ 87.05% |
Financing Cash Flow | 1.2M | ↓ 98.91% |
Sell
Neutral
Buy
Treace Medical Concepts Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Treace Medical Concepts Inc | -10.49% | -57.36% | -55.9% | -80.27% | -81.28% |
Stryker Corporation | 4.54% | 12.8% | 32.62% | 35.95% | 78.95% |
Boston Scientific Corp. | -1.09% | 15.26% | 58.34% | 96.75% | 104.05% |
Edwards Lifesciences Corp. | 3.13% | -20.63% | 0.66% | -42.46% | -13.89% |
Abbott Laboratories | 5.29% | 12.27% | 24.84% | -8.13% | 44.25% |
Medtronic Plc | 2.05% | 10.16% | 22.68% | -25.37% | -15.94% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Treace Medical Concepts Inc | NA | NA | NA | -0.94 | -0.49 | -0.17 | NA | 1.8 |
Stryker Corporation | 38.19 | 38.19 | 2.49 | 12.05 | 0.19 | 0.07 | 0.01 | 52.87 |
Boston Scientific Corp. | 69.44 | 69.44 | 1.53 | 2.46 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 28.62 | 28.62 | 6.15 | 2.53 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 36.05 | 36.05 | 2.2 | 4.67 | 0.14 | 0.06 | 0.02 | 22.6 |
Medtronic Plc | 30.05 | 30.05 | 1.65 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Treace Medical Concepts Inc | Buy | $297.9M | -81.28% | NA | -32.08% |
Stryker Corporation | Buy | $138.5B | 78.95% | 38.19 | 16.34% |
Boston Scientific Corp. | Buy | $123.7B | 104.05% | 69.44 | 11.26% |
Edwards Lifesciences Corp. | Buy | $40.7B | -13.89% | 28.62 | 65.86% |
Abbott Laboratories | Buy | $205.7B | 44.25% | 36.05 | 13.99% |
Medtronic Plc | Buy | $116.1B | -15.94% | 30.05 | 12.06% |
Insights on Treace Medical Concepts Inc
Revenue is down for the last 3 quarters, 62.21M → 44.45M (in $), with an average decrease of 15.4% per quarter
Netprofit is down for the last 3 quarters, -6.28M → -21.20M (in $), with an average decrease of 105.4% per quarter
In the last 1 year, Boston Scientific Corp. has given 59.2% return, outperforming this stock by 115.9%
In the last 3 years, Boston Scientific Corp. has given 96.8% return, outperforming this stock by 177.1%
Morgan Stanley - Brokerage Accounts
Armistice Capital, LLC
BlackRock Inc
William Blair Investment Management, LLC
Vanguard Group Inc
Soleus Capital Management, L.P.
treace medical concepts, inc. is a privately-funded, commercial stage company focused on bringing breakthrough technologies to the high-growth $1.1 billion us market for foot and ankle surgical products. we are committed to operating our business with the highest standards of ethical conduct. we will exceed our customers’ expectations through an innovation-driven, high-velocity approach to solving treatment and surgical problems. with our products and services, our mission is to assist foot and ankle physicians in improving patient outcomes and reducing healthcare costs, while providing a rewarding experience for our employees and an exceptional return for our shareholders.
Organization | Treace Medical Concepts Inc |
Employees | 516 |
CEO | Mr. John T. Treace |
Industry | Healthcare |